PRDX5 and neoplasm: In summary, our experiments suggest that some patients affected by TSC mutation- regulated neoplasms might benefit from auranofin and rapamycin combination therapy, which could potentially prolong remission or slow disease progression via the normalization of Prdx5 levels and ER stress-dependent cellular death.